Lung Transplant Patients Not Given Anti-fungal Preventive Drugs Have Higher Death Risk: Study
In the first year following lung transplantation, anti-fungal drugs reduced mortality risk by half, stated a Mayo Clinic research involving 667 patients who received lung transplants from 2005 to 2018. The findings of the study are published in the Annals of the American Thoracic Society.
The study evaluated anti-fungal preventive medications' effectiveness in lung transplant recipients who are particularly susceptible to invasive fungal infections. These infections are linked to a nearly threefold increase in mortality for lung transplant recipients.
‘Significant reduction in mortality risk among lung transplant recipients who received anti-fungal medications is consistent with several prior studies in hematologic malignancies and bone marrow transplant patients. ’
Study Details
"In our retrospective study, the risk of death within the first year post-transplant is about twice as high in patients not receiving antifungal preventive treatment, compared with those receiving treatment," says Dr. Pennington.
Source: Medindia